Cited by 623Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.

Neuropathology of Parkinson disease

Open access

Dickson, Dennis W.·2018·Parkinsonism & Related Disorders

DOI 10.1016/j.parkreldis.2017.07.033PMC PMC5718208

Open this paper in CoChat — free account

Abstract

Introduction Parkinson's disease (PD) is characterized by bradykinesia, rigidity, postural instability and tremor. Several pathologic processes can produce this syndrome, but neurodegeneration accompanied by neuronal inclusions composed of α-synuclein (Lewy bodies) is considered the typical pathologic correlate of PD.Methods The neuropathologic features of PD are reviewed based upon personal experience and review of the literature. Molecular pathology of PD is summarized from cell biological and animal studies.Results The pathologic feature that correlates with signs and symptoms of PD is neuronal loss in the substantia nigra with dopaminergic denervation of the striatum. Neuronal degeneration in the substantia nigra preferentially affects the ventrolateral cell group that projects to posterolateral putamen and is accompanied by formation of Lewy bodies composed of aggregated α-synuclein. Some patients with PD are found at autopsy to have other pathologic processes, such as multiple system atrophy, progressive supranuclear palsy and cerebrovascular disease (vascular Parkinsonism). The peripheral autonomic nervous system is also affected. The triggering event in PD is unknown, but recent studies suggest a role for loss of nuclear membrane integrity. Once α-synuclein aggregates forms, evidence supports cell-to-cell propagation.Conclusion PD is a multisystem synucleinopathy caused by poorly characterized genetic and environmental factors that produces degeneration in selectively vulnerable neuronal populations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.parkreldis.2017.07.033

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citation
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citation
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Self-citation
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A. A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M. J., Lincoln, S., Kachergus, J. M., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,087
Self-citation

Flagged first, then by citations

Show all 166 references

Sorted by citations

Items 101–200 of 623

Imaging of Substantia Nigra in Parkinson’s Disease: A Narrative Review
Feraco, P., Gagliardo, C., Tona, G. L., Bruno, E., D’Angelo, C., Marrale, M., Poggio, A. D., Malaguti, M. C., Geraci, L., Baschi, R., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11060769 · Cited by 42
Closest horizons of Hsp70 engagement to manage neurodegeneration
Venediktov, A. A., Bushueva, O. Y., Kudryavtseva, V. A., Kuzmin, E. A., Moiseeva, A. V., Baldycheva, A. V., Meglinski, I. V., & Piavchenko, G. A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1230436 · Cited by 44
Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration
González‐Casacuberta, I., Juárez‐Flores, D. L., Morén, C., & Garrabou, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00894 · Cited by 44
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes
Schönecker, S., Brendel, M., Palleis, C., Beyer, L., Höglinger, G. U., Schuh, E., Rauchmann, B., Sauerbeck, J., Rohrer, G., Sonnenfeld, S., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00249 · Cited by 44
Insights into the multifaceted role of circular RNAs: implications for Parkinson’s disease pathogenesis and diagnosis
Doxakis, E. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-021-00265-9 · Cited by 43
Schisandra chinensis protects against dopaminergic neuronal oxidative stress, neuroinflammation and apoptosis via the BDNF/Nrf2/NF-κB pathway in 6-OHDA-induced Parkinson's disease mice
Yan, T., Mao, Q., Zhang, X., Wu, B., Bi, K., He, B., & Jia, Y. (2021) · Food & Function · doi:10.1039/d0fo02836c · Cited by 41
Current radiotracers to image neurodegenerative diseases
Tiepolt, S., Patt, M., Aghakhanyan, G., Meyer, P., Hesse, S., Barthel, H., & Sabri, O. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0070-7 · Cited by 46
Wearable sensors in the diagnosis and study of Parkinson’s disease symptoms: a systematic review
Albán-Cadena, A. C., Villalba-Meneses, F., Pila‐Varela, K. O., Moreno-Calvo, A., Villalba-Meneses, C. P., & Almeida-Galárraga, D. A. (2021) · Journal of Medical Engineering & Technology · doi:10.1080/03091902.2021.1922528 · Cited by 43
N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases
Martínez, M. (2022) · Antioxidants · doi:10.3390/antiox11020416 · Cited by 46
circ-Pank1 promotes dopaminergic neuron neurodegeneration through modulating miR-7a-5p/α-syn pathway in Parkinson’s disease
Liu, Q., Li, Q.-Y., Zhang, R., Wang, H., Li, Y., Liu, Z., Xie, W., Geng, D., & Wang, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04934-2 · Cited by 42
Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson’s disease-like pathology
Cao, Q., Luo, S., Yao, W., Qu, Y., Wang, N., Hong, J., Murayama, S., Zhang, Z., Chen, J., Hashimoto, K., et al. (2022) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.05.037 · Cited by 41
Olfactory Dysfunction in Familial and Sporadic Parkinson's Disease
Chase, B. A., & Markopoulou, K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00447 · Cited by 40
Environmental factors in Parkinson’s disease: New insights into the molecular mechanisms
Yuan, X., Tian, Y., Liu, C., & Zhang, Z. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.12.003 · Cited by 42
Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes
Padilla-Godínez, F. J., Ruiz-Ortega, L. I., & Guerra‐Crespo, M. (2022) · Cells · doi:10.3390/cells11213445 · Cited by 40
Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases
Carles, A., Freyssin, A., Perin-Dureau, F., Rubinstenn, G., & Maurice, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073733 · Cited by 47
Role of mesenchymal stem cell-derived exosomes in the regeneration of different tissues
Huang, D., Shen, H., Xie, F., Hu, D., Jin, Q., Hu, Y., & Zhong, T. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00431-6 · Cited by 43
Epigallocatechin-3-Gallate Protects and Prevents Paraquat-Induced Oxidative Stress and Neurodegeneration in Knockdown dj-1-β Drosophila melanogaster
Martinez-Perez, D. A., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9899-x · Cited by 39
Microglia‐specific knock‐out of NF‐κB / IKK2 increases the accumulation of misfolded α‐synuclein through the inhibition of p62/ sequestosome ‐1‐dependent autophagy in the rotenone model of Parkinson's disease
Rocha, S. M., Kirkley, K. S., Chatterjee, D., Aboellail, T., Smeyne, R. J., & Tjalkens, R. B. (2023) · Glia · doi:10.1002/glia.24385 · Cited by 41
Metformin and Trehalose-Modulated Autophagy Exerts a Neurotherapeutic Effect on Parkinsonʼs Disease
Gopar‐Cuevas, Y., Cárdenas, O. S., Loera‐Arias, M. D. J., Montes‐de‐Oca‐Luna, R., Rodríguez‐Rocha, H., & García‐García, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03530-5 · Cited by 39
Regulatory roles of the miR-200 family in neurodegenerative diseases
Fu, J., Peng, L., Tao, T., Chen, Y., Li, Z., & Li, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109409 · Cited by 39
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 41
Emerging roles of growth differentiation factor‑15 in brain disorders (Review)
Jiang, W., Zhang, Z., He, P., Jiang, L., Chen, J.-Z., Zhang, X.-T., Hu, M., Zhang, Y.-K., & Ouyang, X.-P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10705 · Cited by 40
Causal Relationships Between Osteoarthritis and Senile Central Nerve System Dysfunction: A Bidirectional Two-Sample Mendelian Randomization Study
Cai, Y., Zhang, G., Liang, J., Jing, Z., Zhang, R., Lv, L., & Dang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.793023 · Cited by 38
Association of inflammation/nutrition-based indicators with Parkinson’s disease and mortality
Jia, H., Yin, K., Zhao, J., & Che, F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1439803 · Cited by 37
Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review
Khan, M. S., Nasiripour, S., & Bopassa, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136416 · Cited by 48
Golgi Apparatus: A Potential Therapeutic Target for Autophagy-Associated Neurological Diseases
Deng, S., Liu, J., Wu, X., & Lu, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564975 · Cited by 37
Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson’s Disease
Wu, P., Dong, Y., Chen, J., Guan, T., Cao, B., Zhang, Y., Qi, Y., Guan, Z., & Wang, Y. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00460-9 · Cited by 41
Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease
Minakawa, E. N. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.927994 · Cited by 38
Central modulation of parasympathetic outflow is impaired in de novo Parkinson's disease patients
Tessa, C., Toschi, N., Orsolini, S., Valenza, G., Lucetti, C., Barbieri, R., & Diciotti, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210324 · Cited by 36
Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson’s disease models
Wu, J., Xu, X., Li, Z., Mo, J., Jin, X., & Bao, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108025 · Cited by 37
The Protective Effects of Mogroside V Against Neuronal Damages by Attenuating Mitochondrial Dysfunction via Upregulating Sirtuin3
Luo, H., Peng, C., Xu, X., Peng, Y., Shi, F., Li, Q., Dong, J., & Chen, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02689-z · Cited by 36
Protective Effects of Polysaccharides in Neurodegenerative Diseases
Wang, Y., Chen, R., Yang, Z., Wen, Q., Cao, X., Zhao, N., & Yan, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.917629 · Cited by 40
Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism
Chougar, L., Arsovic, E., Gaurav, R., Biondetti, E., Faucher, A., Valabrègue, R., Pyatigorskaya, N., Dupont, G., Lejeune, F., Cormier‐Dequaire, F., et al. (2022) · Movement Disorders · doi:10.1002/mds.28988 · Cited by 37
Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems
Schreiner, T. G., Menéndez‐González, M., Schreiner, O. D., & Ciobanu, R. C. (2025) · Biomedicines · doi:10.3390/biomedicines13092167 · Cited by 36
Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
Rajamani, K. T., Li, P., Galvis, M. L. E., Labrie, V., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171240 · Cited by 36
HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson’s Disease and Dementia with Lewy Bodies
Bohush, A., Niewiadomska, G., Weis, S., & Filipek, A. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181443 · Cited by 35
Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease
Wang, M., Liu, H., & Ma, Z. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.832854 · Cited by 36
Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models
Zhang, J., Sun, B., Yang, J., Chen, Z., Li, Z., Zhang, N., Li, H., & Shen, L. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12607 · Cited by 34
Respiratory Abnormalities in Parkinson’s Disease: What Do We Know from Studies in Humans and Animal Models?
Kaczyńska, K., Orłowska, M. E., & Andrzejewski, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073499 · Cited by 38
From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer’s and Parkinson’s diseases
Wakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 38
A cynomolgus monkey with naturally occurring Parkinson's disease
Li, H., Su, L., Yang, L., Li, M., Liu, Q., Li, Z., Hu, Y., Li, H., Wu, S., Wang, W., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa292 · Cited by 33
Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies
Lee, S. Y. H., Yates, N. J., & Tye, S. J. (2021) · The Neuroscientist · doi:10.1177/1073858421992265 · Cited by 34
Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio Are Associated with Mild Cognitive Impairment in Parkinson’s Disease: A Single-Center Longitudinal Study
Contaldi, E., Magistrelli, L., Cosentino, M., Marino, F., & Comi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195543 · Cited by 33
Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons
Jiang, P., Gan, M., Yen, S.-H. C., Moussaud, S., McLean, P. J., & Dickson, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1542-4 · Cited by 32
Self-citation
MRI Signs of Parkinson’s Disease and Atypical Parkinsonism
Aludin, S., & Schmill, L.-P. A. (2021) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-1460-8795 · Cited by 32
Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease
Koga, S., Li, F., Zhao, N., Roemer, S. F., Ferman, T. J., Wernick, A. I., Walton, R. L., Faroqi, A. H., Graff‐Radford, N. R., Cheshire, W. P., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12839 · Cited by 32
Self-citation
Therapeutic antisense oligonucleotides for movement disorders
Doxakis, E. (2020) · Medicinal Research Reviews · doi:10.1002/med.21706 · Cited by 34
Search for safer and potent natural inhibitors of Parkinson's disease
Khan, S. T., Ahmed, S., Gul, S., Khan, A., & Al‐Harrasi, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105135 · Cited by 32
VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders
Wang, Y., Qin, X., Han, Y. J., & Li, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113099 · Cited by 33
Deficits in Emotion Recognition and Theory of Mind in Parkinson’s Disease Patients With and Without Cognitive Impairments
Dodich, A., Funghi, G., Meli, C., Pennacchio, M., Longo, C., Malaguti, M. C., Giacopo, R. D., Zappini, F., Turella, L., & Papagno, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866809 · Cited by 32
Progress of Ginsenoside Rb1 in neurological disorders
Ling, G., Zhang, M., Chen, C., Wang, Y., Gao, Q., Li, J., Yuan, H., Jin, W., Lin, W., & Yang, L.-R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1280792 · Cited by 32
Neurophysiology of the brain stem in Parkinson’s disease
Bove, C., & Travagli, R. A. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00056.2019 · Cited by 33
Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies
Sekiya, H., Matsubara, T., Deture, M. A., & Dickson, D. W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00900-6 · Cited by 35
Self-citation
Th17 cells: a promising therapeutic target for Parkinson’s disease?
Prots, I., & Winner, B. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1590336 · Cited by 31
REMOVED: Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
Ozkızılcık, A., Sharma, A., Lafuente, J. V., Muresanu, D. F., Nozari, A., Tian, Z. R., Mössler, H., & Sharma, H. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.014 · Cited by 29
Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease
Duwa, R., Jeong, J., & Yook, S. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00521-3 · Cited by 31
Genkwanin suppresses MPP+-induced cytotoxicity by inhibiting TLR4/MyD88/NLRP3 inflammasome pathway in a cellular model of Parkinson’s disease
Li, Q., Zhang, P., & Cai, Y. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.08.018 · Cited by 30
Region-Specific Neurovascular Decoupling Associated With Cognitive Decline in Parkinson’s Disease
Shang, S., Zhang, H., Feng, Y., Wu, J., Dou, W., Chen, Y., & Yin, X. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.770528 · Cited by 30
Neuropathology of Parkinson’s Disease
Jellinger, K. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_2 · Cited by 31
Disease modification in Parkinsonism: obstacles and ways forward
Höllerhage, M., Klietz, M., & Höglinger, G. U. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02520-6 · Cited by 29
Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease
Peng, H., Chen, S., Wu, S., Shi, X., Ma, J., Yang, H., & Li, X. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120730 · Cited by 29
Improved immunostaining of nanostructures and cells in human brain specimens through expansion-mediated protein decrowding
Valdes, P. A., Yu, C.-C., Aronson, J., Ghosh, D., Zhao, Y., An, B., Bernstock, J. D., Bhere, D., Felicella, M. M., Viapiano, M. S., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.abo0049 · Cited by 37
Roles for α-Synuclein in Gene Expression
Somayaji, M., Lanseur, Z., Choi, S. J., Sulzer, D., & Mosharov, E. V. (2021) · Genes · doi:10.3390/genes12081166 · Cited by 32
Wearable Electrochemical Sensors in Parkinson’s Disease
Asci, F., Vivacqua, G., Zampogna, A., D’Onofrio, V., Mazzeo, A., & Suppa, A. (2022) · Sensors · doi:10.3390/s22030951 · Cited by 29
Brainstem Ventilatory Dysfunction: A Plausible Mechanism for Dyspnea in Parkinson's Disease?
Vijayan, S., Singh, B., Ghosh, S., Stell, R., & Mastaglia, F. L. (2020) · Movement Disorders · doi:10.1002/mds.27932 · Cited by 29
The noradrenergic system is necessary for survival of vulnerable midbrain dopaminergic neurons: implications for development and Parkinson's disease
Hassani, O. K., Rymar, V. V., Nguyen, K. Q., Huo, L., Cloutier, J., Miller, F. D., & Sadikot, A. F. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.014 · Cited by 28
P2X4 receptor participates in autophagy regulation in Parkinson's disease
Zhang, X., Wang, J., Gao, J., Zhang, X., Dou, K., Shi, W., & Xie, A. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.313053 · Cited by 28
Mushroom Polysaccharides as Potential Candidates for Alleviating Neurodegenerative Diseases
Jiang, X., Li, S., Feng, X., Li, L., Hao, J., Wang, D., & Wang, Q. (2022) · Nutrients · doi:10.3390/nu14224833 · Cited by 29
Does vitamin D protect or treat Parkinson’s disease? A narrative review
Al-Kuraishy, H. M., Al-Gareeb, A. I., Selim, H. M., Alexiou, A. T., Papadakis, M., Negm, W. A., & Batiha, G. E. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02656-6 · Cited by 28
Clinical Evaluation in Parkinson’s Disease: Is the Golden Standard Shiny Enough?
Kanellos, F. S., Tsamis, K. I., Rigas, G., Simos, Y. V., Katsenos, A. P., Kartsakalis, G., Fotiadis, D. I., Vezyraki, P., Peschos, D., & Konitsiotis, S. (2023) · Sensors · doi:10.3390/s23083807 · Cited by 27
Study of the gut microbiome in Egyptian patients with Parkinson’s Disease
Mehanna, M., AbuRaya, S., Ahmed, S. M., Ashmawy, G. A. H. O., Ibrahim, A. E., & AbdelKhaliq, E. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02933-7 · Cited by 30
Candidate biomarkers for Parkinson's disease
Khodadadian, A., Hemmati-Dinarvand, M., Kalantary‐Charvadeh, A., Ghobadi, A., & Mazaheri, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.026 · Cited by 27
Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review
Liu, S., Li, L., Zhuang, J.-L., Li, M.-M., Ye, L., Chen, X., Lin, S., & Chen, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.950715 · Cited by 28
Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis
Jin, J., Su, D., Zhang, J., Li, X., & Feng, T. (2023) · Journal of Neurology · doi:10.1007/s00415-022-11556-3 · Cited by 26
Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson’s Disease
Yadav, S. K., Jauhari, A., Singh, N., Pandey, A. K., Sarkar, S., Pandey, S., Garg, R. K., Parmar, D., & Yadav, S. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01362-4 · Cited by 26
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism
Chittoor-Vinod, V. G., Nichols, R. J., & Schüle, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031045 · Cited by 26
Deep Brain Stimulation–Withdrawal Syndrome in Parkinson’s Disease: Risk Factors and Pathophysiological Hypotheses of a Life-Threatening Emergency
Grimaldi, S., Eusébio, A., Carron, R., Régis, J.-M., Velly, L. J., Azulay, J., & Witjas, T. (2022) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2022.09.008 · Cited by 25
Pattern of tyrosine hydroxylase expression during aging of mesolimbic pathway of the rat
Norrara, B., Fiuza, F. P., Arrais, A. C., da Costa, I. M., dos Santos, J. R., Engelberth, R. C. G. J., Cavalcante, J. S., Gúzen, F. P., Cavalcanti, J. R. L. D. P., & Freire, M. A. M. (2018) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.05.004 · Cited by 28
Altered gastric tone and motility response to brain-stem dopamine in a rat model of parkinsonism
Bove, C., Anselmi, L., & Travagli, R. A. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00076.2019 · Cited by 28
Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors
Chen, X., Zhu, H., Bao, K., Li, J., Zhu, H., Ying, M., He, Q., Yang, B., Sheng, R., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00600-5 · Cited by 25
A Fluorescence‐Based Sensor Assay that Monitors General Protein Aggregation in Human Cells
Pereira, M., Tomé, D., Domingues, A. S., Varanda, A. S., Paulo, C. G., Santos, M. A. S., & Soares, A. R. (2018) · Biotechnology Journal · doi:10.1002/biot.201700676 · Cited by 23
Open questions on the nature of Parkinson’s disease: from triggers to spreading pathology
Mou, L., Ding, W., & Fernández-Fúnez, P. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106210 · Cited by 28
Cell-free microRNAs in Parkinson’s disease: potential biomarkers that provide new insights into disease pathogenesis
Doxakis, E. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101023 · Cited by 25
Motor asymmetry related cerebral perfusion patterns in Parkinson's disease: An arterial spin labeling study
Shang, S., Wu, J., Zhang, H., Chen, H., Cao, Z., Chen, Y., & Yin, X. (2020) · Human Brain Mapping · doi:10.1002/hbm.25223 · Cited by 25
GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
Ugale, V. G., Dhote, A. M., Narwade, R., Khadse, S. C., Reddy, P. N., & Shirkhedkar, A. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210309141627 · Cited by 22
The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology
Obergasteiger, J., Castonguay, A.-M., Pizzi, S., Magnabosco, S., Frapporti, G., Lobbestael, E., Baekelandt, V., Hicks, A. A., Pramstaller, P. P., Gravel, C., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00484-2 · Cited by 24
Patterns of TDP ‐43 Deposition in Brains with LRRK2 G2019S Mutations
Agin‐Liebes, J., Hickman, R. A., Vonsattel, J. P., Faust, P. L., Flowers, X. E., Utkina-Sosunova, I. V., Ntiri, J., Mayeux, R. P., Surface, M., Marder, K. S., et al. (2023) · Movement Disorders · doi:10.1002/mds.29449 · Cited by 23
High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein
Jia, F., Song, N., Wang, W., Du, X., Chi, Y., & Jiang, H. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00097 · Cited by 26
Efficacy of Specific Trunk Exercises in the Balance Dysfunction of Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
López‐Liria, R., Vega-Tirado, S., Valverde-Martínez, M. D. L. Á., Mateo, A. C., Martínez-Martínez, A. M., & Pérez, P. R. (2023) · Sensors · doi:10.3390/s23041817 · Cited by 23
A multiple hits hypothesis for memory dysfunction in Parkinson disease
Citro, S., Lazzaro, G. D., Cimmino, A. T., Giuffrè, G. M., Marra, C., & Calabresi, P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00905-z · Cited by 23
The effects of cholesterol and statins on Parkinson’s neuropathology: a narrative review
Al-Kuraishy, H. M., Fahad, E. H., Al‐Windy, S., El-Sherbeni, S. A., Negm, W. A., & Batiha, G. E. (2024) · Inflammopharmacology · doi:10.1007/s10787-023-01400-z · Cited by 23
The dual role of c‐src in cell‐to‐cell transmission of α‐synuclein
Choi, Y. R., Kim, J., Kang, S., Noh, H. R., Jou, I., Joe, E.-H., & Park, S. M. (2020) · EMBO Reports · doi:10.15252/embr.201948950 · Cited by 28
Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs
Jin, Y., Li, F., Li, Z., Ikezu, T. C., O’Leary, J., Selvaraj, M., Zhu, Y., Martens, Y. A., Koga, S., Santhakumar, H., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk3700 · Cited by 26
Self-citation
Toward a biological definition of neuronal and glial synucleinopathies
Soto, C. A., Mollenhauer, B., Hansson, O., Kang, U. J., Alcalay, R. N., Standaert, D. G., Trenkwalder, C., MAREK, K. L., Galasko, D. R., & Poston, K. L. (2025) · Nature Medicine · doi:10.1038/s41591-024-03469-7 · Cited by 25
Genomic Analysis Identifies New Loci Associated With Motor Complications in Parkinson's Disease
Ryu, H. S., Park, K. W., Choi, N., Kim, J., Park, Y. M., Jo, S., Kim, M. J., Kim, Y. J., Kim, J., Kim, K., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00570 · Cited by 22
Movement of prion‐like α‐synuclein along the gut–brain axis in Parkinson's disease: A potential target of curcumin treatment
Chetty, D., Abrahams, S., van Coller, R., Carr, J. A., Kenyon, C. P., & Bardien, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15324 · Cited by 22
Impact of the apelin/APJ axis in the pathogenesis of Parkinson’s disease with therapeutic potential
Angelopoulou, E., Paudel, Y. N., Bougea, A. M., & Piperi, C. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24895 · Cited by 24
Using an unbiased symbolic movement representation to characterize Parkinson’s disease states
Abrami, A., Heisig, S., Ramos, V. F. M. L., Thomas, K. C., Ho, B. K., & Caggiano, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-64181-3 · Cited by 20
Melatonin Increases Life Span, Restores the Locomotor Activity, and Reduces Lipid Peroxidation (LPO) in Transgenic Knockdown Parkin Drosophila melanogaster Exposed to Paraquat or Paraquat/Iron
Ortega‐Arellano, H. F., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00397-z · Cited by 22
Aberrant Neurogliovascular Unit Dynamics in Cerebral Small Vessel Disease: A Rheological Clue to Vascular Parkinsonism
Nassir, C. M. N. C. M., Damodaran, T. K., Yusof, S. R., Norazit, A., Chilla, G. S. V. N., Huen, I., Nagaraja, B. P. K., Ibrahim, N. M., & Mustapha, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081207 · Cited by 22

Authors: Dickson, D. W.
Affiliations: Mayo Clinic (US)
Corresponding author: Dickson, Dennis W.
ORCID: Dickson, Dennis W.
Venue: Parkinsonism & Related Disorders
Publisher: Elsevier BV
Published: 2018-01
Volume: 46
Pages: S30-S33
ISSN: 1353-8020 (ISSN-L)
DOI: 10.1016/j.parkreldis.2017.07.033
PMC: PMC5718208
OpenAlex: W2501464909
Cited by: 623
References: 166
Citations by year: 2026: 53 · 2025: 80 · 2024: 80 · 2023: 82 · 2022: 100 · 2021: 91 · 2020: 63 · 2019: 39 · 2018: 22
FWCI: 4.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 318 d)
Locations: Parkinsonism & Related Disorders (acceptedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: NINDS (P50-NS072187)
Mangurian Foundation Lewy Body Dementia Program
CurePSP/Tau Consortium Brain Bank
The Robert E. Jacoby Professorship
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: Parkinson's disease, neuropathology
MeSH terms: Neuropathology, Brain, Humans, Parkinson Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuropathology of Parkinson disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks